Analyst Report: Amgen Inc
Quick Take
Analyst report highlights Amgen's strong market position and growth potential.
Key Points
- Amgen shows robust financial performance.
- Pipeline includes promising new therapies.
- Market trends favor biotech sector growth.
📖 Reader Mode
~2 min read
Argus
•
May 19, 2026
Amgen Inc.: Raising EPS estimates for 2026 and 2027
Sector(s)
Healthcare
Rating
Earnings Estimate
Current Price
$332.08
Price Target
Summary
Amgen, based in Thousand Oaks, California, is a leading global biotech company. Its key products include Prolia, Enbrel, Otezla, Repatha, Xgeva, Tepezza, Evenity, Blincyto, Kyprolis, Kry
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
Analyst Profile
Jasper Hellweg
Associate Analyst: Growth Pharmaceutical, Medical Technology & Financial Technology
At Argus Research, Jasper covers the Growth Pharmaceutical, Medical Technology, and Financial Technology companies. He received his undergraduate degree from Boston University, graduating cum laude with a Bachelor of Science degree in Business Administration with concentrations in Entrepreneurship and Marketing. Prior to joining Argus, Jasper worked in a variety of industries, ranging from investment tradeshow management to musical instrument manufacturing. He started his career at Argus in the Research department and has since widened his scope to also include becoming a regular contributor for the Market Movers and Market Digest publications, the Vickers Weekly Insider Report and Argus' bespoke research on IPOs.
— Originally published at finance.yahoo.com
More from Yahoo Finance
See more →
These Super Stocks Could Be the Biggest Winners in the AI Inference and Agentic AI Economy
The article highlights top stocks poised for growth in the AI inference and agentic AI sectors.
